{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:58:51Z","timestamp":1747169931838,"version":"3.40.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.rceng.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:08:18Z","timestamp":1717607298000},"page":"474-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-3700","authenticated-orcid":false,"given":"C.A.","family":"Ca\u00f1as","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Posso-Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"P\u00e9rez-Uribe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Erazo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.rceng.2024.06.001_bib0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.rceng.2024.06.001_bib0010","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrrheum.2009.141","article-title":"B-cell-directed therapies for autoimmune disease","volume":"5","author":"D\u00f6rner","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rceng.2024.06.001_bib0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12016-007-8028-z","article-title":"Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?","volume":"34","author":"Galarza","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.rceng.2024.06.001_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JOP.2010.000042","article-title":"Off-label use of rituximab in a multipayer insurance system","volume":"7","author":"Van Allen","year":"2011","journal-title":"J Oncol Pract"},{"issue":"5 Pt 1","key":"10.1016\/j.rceng.2024.06.001_bib0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"issue":"25","key":"10.1016\/j.rceng.2024.06.001_bib0030","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.rceng.2024.06.001_bib0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rceng.2024.06.001_bib0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse reactions to biologic therapy","volume":"37","author":"Patel","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"10.1016\/j.rceng.2024.06.001_bib0045","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00296-021-04847-x","article-title":"Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study","volume":"41","author":"Wade","year":"2021","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.rceng.2024.06.001_bib0050","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/rheumatology\/key394","article-title":"Recommendations for the management of secondary hypogammaglobulinaemia due to B-cell targeted therapies in autoimmune rheumatic diseases","volume":"58","author":"Wijetilleka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"author":"U.S Department of health and human services","key":"10.1016\/j.rceng.2024.06.001_bib0055"},{"issue":"3","key":"10.1016\/j.rceng.2024.06.001_bib0060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jbi.2009.06.004","article-title":"Adverse events in medicine: easy to count, complicated to understand, and complex to prevent","volume":"44","author":"Amalberti","year":"2011","journal-title":"J Biomed Inform"},{"issue":"11","key":"10.1016\/j.rceng.2024.06.001_bib0065","first-page":"15234","article-title":"Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience","volume":"8","author":"\u00d6zkan","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"10.1016\/j.rceng.2024.06.001_bib0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/mrcr\/rxac066","article-title":"Lymphoid follicular hyperplasia in patients with systemic lupus erythematosus after multiple cycles of rituximab","volume":"7","author":"Ruiz-Ord\u00f3\u00f1ez","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"issue":"3","key":"10.1016\/j.rceng.2024.06.001_bib0075","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.rmed.2011.11.009","article-title":"Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients","volume":"106","author":"Kang","year":"2012","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.rceng.2024.06.001_bib0080","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s40800-018-0087-y","article-title":"Secondary hypogammaglobulinemia after rituximab for neuromyelitis optica: a case report","volume":"5","author":"Farhat","year":"2018","journal-title":"Drug Saf Case Rep"},{"issue":"6","key":"10.1016\/j.rceng.2024.06.001_bib0085","doi-asserted-by":"crossref","first-page":"310","DOI":"10.5603\/ARM.a2018.0050","article-title":"Development of bronchiectasis during long-term rituximab treatment for rheumatoid arthritis","volume":"86","author":"Santos","year":"2018","journal-title":"Adv Respir Med"},{"issue":"3","key":"10.1016\/j.rceng.2024.06.001_bib0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7326\/0003-4819-98-3-323","article-title":"Lupus cystitis: primary bladder manifestations of systemic lupus erythematosus","volume":"98","author":"Orth","year":"1983","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rceng.2024.06.001_bib0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Hematol"},{"issue":"18","key":"10.1016\/j.rceng.2024.06.001_bib0100","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMra012519","article-title":"Bronchiectasis","volume":"346","author":"Barker","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887424000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887424000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T21:10:45Z","timestamp":1722633045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887424000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2254887424000791"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2024.06.001","relation":{},"ISSN":["2254-8874"],"issn-type":[{"type":"print","value":"2254-8874"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2024.04.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}